Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 13 of 15

 
 

Jazz Pharmaceuticals (NASDAQ:JAZZ)

Consensus Rating
Moderate Buy
Rating Score
2.9
Ratings Breakdown
13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$177.00 (44.7% Upside)

About Jazz Pharmaceuticals

Jazz Pharmaceuticals logoJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
12/12/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$163.00 ➝ $163.00
12/12/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$140.00 ➝ $175.00
12/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$207.00 ➝ $207.00
12/10/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$179.00 ➝ $179.00
11/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
11/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$207.00 ➝ $207.00
11/21/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$166.00 ➝ $163.00
11/18/2024Robert W. BairdBoost Price TargetOutperform ➝ Outperform$154.00 ➝ $162.00
11/7/2024TD CowenLower Price TargetBuy ➝ Buy$200.00 ➝ $195.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$207.00 ➝ $207.00